High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs

Table 1 Clinicopathological features of the 176 patients with triple-negative breast cancer

Variables	All patients	Met	Non-met	Univariate			Multivariate
Variables	All patients	Met	Non-met	OR	95% CI	P value	OR	95% CI	P value
n	176	29	147
Age, mean (range), y	58.9 (24–89)	55.3	59.6	0.3^b	0.04–1.5	0.140	0.3^b	0.02–4.8	0.400
Histology
NST	141 (80%)	23	118	0.9	0.4–2.7	0.906
Others	35 (20%)	6	29
Tumor size, mean (range), mm	21.9 (0–75)	34.2	19.5	34.4^b	6.2–214.7	< 0.001	60.6^b	5.5–909.1	< 0.001
Lymph node metastasis
Yes	52 (30%)	17	35	4.4	1.9–10.3	< 0.001	3.7	1.3–10.9	0.014
No	121 (70%)	12	109
Not evaluated	3	0	3
Tumor grade
High	70 (48%)	16	54	1.9	0.8–4.9	0.151	1.6	0.5–5.0	0.453
Low	67 (52%)	9	58
Not evaluated	39	4	35
Ki67 LI, mean (range), %	57.3 (0–100)	61.7	56.4	1.9^b	0.5–8.8	0.376
TIL, mean (range), %	43.0 (0–100)	31.6	45.2	0.1	0.02–0.6	0.011	0.1	0.004–0.6	0.012
ALC, median (range), μL⁻¹	1640 (519–3917)	1589	1645	0.4^b	0.03–3.9	0.460
PLR, median (range)	143 (56–477)	145	137	4.3^b	0.3–47.2	0.241	3.9^b	0.1–102.0	0.435
NLR, median (range)	2.1 (0.9–11.9)	2.2	2.1	1.8^b	0.1–29.8	0.702
Adjuvant chemotherapy
Yes	132^a (75%)	26	106	3.4	1.1–14.6	0.032	2.3	0.5–13.5	0.272
No	44 (25%)	3	41
Chemotherapy regimens^a
A + T	79 (60%)	20	59	2.7^c	1.0–7.7	0.041
A alone	47 (36%)	5	42
T alone	6 (4%)	1	5

Values are n (%) unless otherwise indicated
^aIncludes 59 patients who received preoperative chemotherapy
^bRange of the odds ratio
^cA + T versus A alone/T alone
A anthracycline-based regimen, ALC absolute lymphocyte count, CI confidence interval, LI labeling index, Met patients who developed distant metastases, NLR neutrophil-to-lymphocyte ratio, non-Met patients free from distant metastases, NST no special type, OR odds ratio, PLR platelet-to-lymphocyte ratio, T taxane, TIL tumor-infiltrating lymphocyte

ISSN: 1465-542X